PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 186 filers reported holding PDL BIOPHARMA INC in Q3 2017. The put-call ratio across all filers is 1.44 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $824,000 | -55.7% | 333,728 | -43.7% | 0.32% | -5.6% |
| Q2 2016 | $1,862,000 | -29.7% | 592,849 | -25.5% | 0.34% | -10.5% |
| Q1 2016 | $2,649,000 | -54.6% | 795,409 | -51.8% | 0.38% | -39.3% |
| Q4 2015 | $5,838,000 | +48.7% | 1,649,083 | +111.3% | 0.63% | +66.4% |
| Q3 2015 | $3,925,000 | +4.8% | 780,281 | +34.0% | 0.38% | +3.3% |
| Q2 2015 | $3,745,000 | -7.4% | 582,438 | +1.3% | 0.37% | -7.6% |
| Q1 2015 | $4,044,000 | +183.2% | 574,801 | +210.3% | 0.40% | +191.2% |
| Q4 2014 | $1,428,000 | +203.2% | 185,225 | +193.9% | 0.14% | +231.7% |
| Q3 2014 | $471,000 | -87.8% | 63,029 | -84.1% | 0.04% | -86.5% |
| Q2 2014 | $3,847,000 | +85.5% | 397,392 | +59.2% | 0.30% | +121.2% |
| Q1 2014 | $2,074,000 | -61.9% | 249,550 | -61.3% | 0.14% | -46.7% |
| Q4 2013 | $5,437,000 | +126.5% | 644,214 | +114.0% | 0.26% | +135.8% |
| Q3 2013 | $2,400,000 | -63.9% | 301,078 | -65.1% | 0.11% | -61.1% |
| Q2 2013 | $6,653,000 | – | 861,769 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |